First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $1M — -62.8% growth in a single year.
What Moves the Stock
1BMF-219 clinical trial data releases - Phase 1/2 safety, tolerability, and preliminary efficacy results in AML/ALL patients (response rates, duration of response, adverse event profiles)
2Partnership or licensing deal announcements - upfront payments, milestone structures, and validation from larger pharmaceutical companies signal asset value
3Equity financing events - dilution from capital raises to extend runway, with pricing and terms indicating investor confidence or desperation
4Competitive menin inhibitor data - results from Syndax Pharmaceuticals (revumenib), Kura Oncology (ziftomenib), or other menin programs affecting category perception
5FDA regulatory feedback - IND clearances, clinical hold resolutions, or breakthrough therapy designations accelerating development timelines
6No current revenue - pre-commercial clinical-stage company
7Future potential: BMF-219 licensing deals or partnerships (estimated industry standard: $50-200M upfront for Phase 2 assets)
8Future potential: Product sales post-approval (menin inhibitor market estimated $2-5B annually across oncology and diabetes indications)
growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds…
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (BMF-219 revenues…
Watch on earnings: BMF-219 Phase 1/2 trial enrollment rates and expected data readout dates (track via clinicaltrials.gov and company presentations), Cash and marketable securities balance versus quarterly burn rate - calculate runway to next financing, Nasdaq Biotechnology Index (NBI) performance - sector sentiment indicator affecting financing windows and valuation multiples.
One Sentence Summary:
Biomea Fusion: the story is balanced — bmf-219 clinical trial data releases - phase 1/2 safety, tolerability, and preliminary efficacy results in aml/all patients (response rates.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.